F8 and hemophilia: However, further investigation and possible modulation of anti-FVIII immune responses in pre-clinical models is anticipated to further reduce the risk of inducing such responses in humans and in view of future application of LV gene therapy to previously untreated hemophilia patients that are naïve to FVIII.